Loading...
CD44v6, a variant isoform of the CD44 cell surface glycoprotein, has gained widespread recognition as a powerful tumor metastasis marker. Its overexpression in various malignancies makes it a prime candidate for cancer diagnostics, targeted therapy, and biomarker-driven research.
Gentaur
Scientific Publications
CD44v6 is an alternative splice variant of the CD44 gene involved in cell-cell interaction, migration, and adhesion. While the standard CD44 (CD44s) is broadly expressed in many tissues, CD44v6 expression is restricted to pathological states, particularly :
Researchers and oncologists focus on CD44v6 due to its:
CD44v6 antibodies are used in flow cytometric analysis to quantify cancer stem cells and tumor heterogeneity.
Source : ResearchGate
CD44v6 mRNA levels are quantified via qPCR to monitor gene expression in patient samples or in vitro cancer models.
Source : ResearchGate : "Recent studies demonstrate that FOLFOX treatment (5-FU + Oxaliplatin) upregulates CD44v6 mRNA expression in colorectal cancer (CRC) cell lines. Using qPCR and RT-PCR, researchers observed a significant increase in CD44v6 levels in FOLFOX-resistant (FR) cells compared to sensitive (S) counterparts. Notably:
-SW480-FR, SW480-5FUR, and SW480-OXAR cells showed higher CD44v6 expression than untreated controls.
-Semi-quantitative PCR confirmed the presence of CD44v6-specific splice variants (e.g., c5v6c7, c5v6v7v8c7).
-IC50 values for 5-FU and OXA were significantly higher in resistant cells, correlating with elevated CD44v6.
-All gene expression was normalized to GAPDH and results were statistically significant (*P < 0.05).
These findings support CD44v6 as a predictive marker of chemoresistance and a potential therapeutic target in CRC."
Researchers use CD44v6 ELISA kits to assess expression levels in tissue extracts and blood, aiding in prognostic biomarker profiling.
CD44v6 is often co-expressed with CD133, ALDH1, and EpCAM, making it a crucial marker for cancer stem-like cells.
